Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo

News

The Lancet Diabetes & Endocrinology Commission on Clinical Obesity
Diabetes, HI-MAG, IDO,

Re-Defining Obesity as a Disease

A new report of the Commission on Clinical Obesity, published in The Lancet Diabetes & Endocrinology and endorsed by over 75 medical organizations, has introduced a transformative framework that addresses the limitations of traditional BMI-based…

read more
Environmental Health, EPI,

Interview with Alexandra Schneider: Heavy Rain, Heat, and Cold Stress Health

Interview with Dr. Alexandra Schneider about the effects of extreme weather conditions on cardiovascular diseases, such as heart attacks and strokes.

read more
Dr. Alexandra Schneider
Lipid nanoparticles
New Research Findings, Bioengineering, iBIO,

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side effects? Researchers at Helmholtz Munich, Ludwig-Maximilians-Universität (LMU) and Technical University Munich (TUM) have…

read more
Awards & Grants, Computational Health, ICB,

Dr. Steffen Schneider Named Early Career Scientist of the Year 2024

Steffen Schneider from the Institute of Computational Biology at Helmholtz Munich has been named the "Early Career Scientist of the Year 2024" by academics. He received this honor for his outstanding research in artificial intelligence and…

read more
Porträt von Steffen Schneider
HMGU_Icon_Diabetes_1
Featured Publication, Diabetes, IDF,

Definition of Dysglycemia in Pre-symptomatic Type 1 Diabetes: A Guide to the Timing of Interventional Therapies

The clinical onset of type 1 diabetes is preceded by presymptomatic stages, that are marked by the presence of two or more islet autoantibodies. Stage 1 is characterized by normal blood glucose levels, while stage 2 is marked by dysglycemia. However,…

read more
Transfer, New Research Findings, Molecular Targets and Therapeutics,

Start-up EBViously founded

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV). The aim is to protect people from a range of serious…

read more
Eppstein Barr Virus

Press Contact

COMS Communications & Strategic Relations

Ingolstädter Landstr. 1